profit from every $100 of sales.
$0$100
Quantum BioPharma
$1.94-3.96% today
-77.5% in 1 year
1-year low $1.941-year high $11.41
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Quantum BioPharma sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$26.2 million of profit last year.
SalesProfit
Quantum BioPharma vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Quantum BioPharma | No profit yet | ||
 Merck KGaA | 25.9× · Fair price | ||
 Takeda Pharmaceutical | 98.8× · Very expensive | ||
 Galderma Group | 89.1× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.8× · Expensive |
AI analysis
An AI analyst reads Quantum BioPharma's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -27 | -20 | -16 | -15 | |
| -22 | -16 | -14 | -26 | |
| -24 | -18 | -14 | -26 | |
| -39.61 | -29.93 | -13.12 | -8.20 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 38 | 17 | 17 | 11 |
| Cash | 17 | 3 | 6 | 2 |
| Total debt | 1 | 0 | 1 | 2 |
| Total liabilities | 8 | 5 | 7 | 6 |
| 31 | 13 | 11 | 7 | |
| 1 | 1 | 1 | 3 | |
| -67.8% | -106.1% | -95.5% | -236.4% | |
| -77.3% | -135.2% | -123.7% | -378.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -28 | -11 | -7 | -8 | |
| 0 | – | – | – | |
| -29 | -11 | -7 | -8 | |
| Dividends paid | – | – | – | – |
| 2 | 3 | 0 | 0 | |
| 2 | 4 | 0 | 3 |
Valuation
- –
- –
- –
- 36.7×
- –
- –
- –
- -67.2%
- -209.8%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- 2,682.3%
- -137.2%
- -622.7%
- -207.1%
- 1,038.7%
- –
Growth
- –
- –
- −21.9%
- –
- +57.2%
Financial health
- 0.2×
- 1.46
- 5.8%
- -32.2×
- 0.63
- 0.63
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 888
Bottom 1%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -3.06 | -0.49 | −524.0% |
| Mar 26, 2026 | -0.71 | -1.02 | +30.5% |
| Nov 7, 2025 | -1.25 | -0.20 | −525.0% |
| Aug 6, 2025 | -3.23 | -0.17 | −1,800.0% |
| May 14, 2025 | -1.41 | -0.37 | −281.1% |
| Mar 28, 2025 | -2.89 | -0.80 | −261.3% |
| Aug 14, 2024 | -5.20 | -3.90 | −33.3% |
| May 14, 2024 | -3.25 | -3.25 | +0.0% |
News
Quantum Computing’s Next Winners May Not Be Quantum StocksYahoo Finance · Nov 11, 2026Quantum projects fiscal Q3 2027 revenue of $91M±$2M while targeting 43% gross margin in 18 monthsSeeking Alpha · Nov 10, 2026Should You Forget IonQ and Buy These 2 Quantum Computing Stocks Instead?Yahoo Finance · Nov 8, 2026Wall Street's Biggest Bubble Looks Ready to Burst, and I Don't Mean AI or Quantum ComputingYahoo Finance · Nov 8, 20263 Millionaire-Maker Quantum Computing StocksYahoo Finance · Nov 8, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/6Passes 0 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
18No pass
Benjamin Graham
14No pass
Philip Fisher
29No pass
Peter Lynch
38No pass
Joel Greenblatt
–Not enough data
Charlie Munger
15No pass
Terry Smith
13No pass
Questions about Quantum BioPharma
Is Quantum BioPharma a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Quantum BioPharma AI analysis
What does Quantum BioPharma do?
Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. It is in Drug Manufacturers - Specialty & Generic.
Does Quantum BioPharma pay a dividend?
No. Quantum BioPharma does not pay a dividend at the moment.
Is Quantum BioPharma stock halal?
Yes. Quantum BioPharma passes our halal screen: its business is permitted and its debt is 15% of its market value, under the 30% limit. How we check
How has Quantum BioPharma stock done over the past year?
Down 77.5% over the past twelve months, to $1.94. It traded between $1.94 and $11.41 and is 83.0% below its high.
Who are Quantum BioPharma's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Quantum BioPharma's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.